These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32669219)

  • 1. Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis.
    Salwan A; Hagemeier NE; Tudiver F; Dowling-McClay K; Foster KN; Arnold J; Alamian A; Pack RP
    J Am Pharm Assoc (2003); 2020; 60(6):e173-e178. PubMed ID: 32669219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care physicians' opioid-related prevention behaviors and intentions: A descriptive analysis.
    Melton TC; Hagemeier NE; Tudiver FG; Foster KN; Arnold J; Brooks B; Alamian A; Pack RP
    J Opioid Manag; 2022; 18(1):75-83. PubMed ID: 35238016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.
    Muzyk A; Smothers ZPW; Collins K; MacEachern M; Wu LT
    Subst Abus; 2019; 40(4):476-483. PubMed ID: 31418645
    [No Abstract]   [Full Text] [Related]  

  • 4. Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder.
    Zalmai R; Hill LG; Loera LJ; Mosgrove Q; Brown C
    J Am Pharm Assoc (2003); 2023; 63(5):1558-1565.e4. PubMed ID: 37331654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.
    Irwin AN; Novak K; Alley L; Havlin T; O'Kane N; Johnston K; Hildebran C; Carson J; Hartung DM
    J Am Pharm Assoc (2003); 2020; 60(3):450-455.e3. PubMed ID: 31919007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention.
    Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M
    J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing pharmacists' knowledge, attitudes, and practices of opioid management within different patient populations.
    Martin SE; Hughes TD; Roller J; Ferreri SP
    J Am Pharm Assoc (2003); 2024; 64(2):414-421.e1. PubMed ID: 38049067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose.
    Skoy E; Werremeyer A; Steig J; Eukel H; Frenzel O; Strand M
    Subst Abus; 2021; 42(4):672-677. PubMed ID: 33044896
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacists' and prescribers' neonatal abstinence syndrome (NAS) prevention behaviors: a preliminary analysis.
    Hagemeier NE; Click IA; Flippin H; Gilliam H; Ross A; Basden JA; Carico R
    Int J Clin Pharm; 2018 Feb; 40(1):20-25. PubMed ID: 29209864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach.
    Varisco TJ; Downs CG; Rathburn KR; Fleming ML; Thornton JD
    Int J Drug Policy; 2020 Sep; 83():102827. PubMed ID: 32589581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
    Haggerty LC; Gatewood SS; Goode JKR
    J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication.
    Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP
    Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
    Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
    Smith A; Hansen J; Colvard M
    J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
    Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
    J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.